Cargando…

Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity

Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehring, Kalle, Miki, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960985/
https://www.ncbi.nlm.nih.gov/pubmed/33268817
http://dx.doi.org/10.1038/s41416-020-01194-9
_version_ 1783665158577455104
author Gehring, Kalle
Miki, Hiroaki
author_facet Gehring, Kalle
Miki, Hiroaki
author_sort Gehring, Kalle
collection PubMed
description Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically inactive PRL mutant that retains oncogenicity in a mouse model promises to resolve the question of whether PRLs act as phosphatases or pseudo-phosphatases in different cancer models.
format Online
Article
Text
id pubmed-7960985
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79609852021-12-03 Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity Gehring, Kalle Miki, Hiroaki Br J Cancer Comment Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically inactive PRL mutant that retains oncogenicity in a mouse model promises to resolve the question of whether PRLs act as phosphatases or pseudo-phosphatases in different cancer models. Nature Publishing Group UK 2020-12-03 2021-03-16 /pmc/articles/PMC7960985/ /pubmed/33268817 http://dx.doi.org/10.1038/s41416-020-01194-9 Text en © Cancer Research UK 2020, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Comment
Gehring, Kalle
Miki, Hiroaki
Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
title Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
title_full Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
title_fullStr Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
title_full_unstemmed Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
title_short Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
title_sort phosphatase, pseudo-phosphatase, or both? understanding prl oncogenicity
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960985/
https://www.ncbi.nlm.nih.gov/pubmed/33268817
http://dx.doi.org/10.1038/s41416-020-01194-9
work_keys_str_mv AT gehringkalle phosphatasepseudophosphataseorbothunderstandingprloncogenicity
AT mikihiroaki phosphatasepseudophosphataseorbothunderstandingprloncogenicity